Biomarker in Irritable Bowel Diseases Diagnostic Market: Introduction
· Irritable or Inflammatory bowel disease (IBD) is a chronic disease, which is used to describe disorders that involve chronic inflammation of the digestive tract. Types of IBD include ulcerative colitis and Crohn's disease. Fecal and serologic biomarkers can be used in the diagnosis and management of inflammatory bowel disease (IBD).
Read Report Overview - https://www.transparencymarketresearch.com/biomarker-in-irritable-bowel-diseases-diagnostic-market.html
Key Drivers and Restraints of Global Biomarker in Irritable Bowel Diseases Diagnostic Market
· High prevalence of IBD boost the market. In Europe, an estimated 2.5 to 3 million people are affected by inflammatory bowel disease per year. Highest incidence and prevalence of IBD is observed in Scandinavia and the U.K. According to IBD Support Australia Incorporated, around 61,000 people in Australia are affected by inflammatory bowel disease, of which around 28,000 people are affected by Crohn’s disease and 33,000 are affected by ulcerative colitis.
· Newer biomarkers are expected to offer significant opportunities. According to a study presented at Digestive Disease Week, the Mucosal Healing Index, a serum-based biomarker assay, demonstrated efficacy in identifying mucosal inflammation and similar accuracy to fecal calprotectin in patients with Crohn’s disease.
Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78169
· However, economic barriers in underdeveloped & developing countries may hamper the market. A huge diversity of health care quality is observed in different geographic areas in Asia, Africa, Latin America, and the Middle East owing to economic imbalance. In certain regions, limited patient access to healthcare facilities, poor physician and patient awareness about disease, and limited availability of diagnostic modalities may delay diagnosis. This is estimated to hamper the in-vitro inflammatory bowel disease diagnostic market during the forecast period.
Stool-based biomarkers to dominate global biomarker in irritable bowel diseases diagnostic market
· Based on type, the global biomarker in irritable bowel diseases diagnostic market can be divided into blood-based biomarker and stool-based biomarker. The blood-based biomarker segment can be further sub-segmented into C-reactive protein, erythrocyte sedimentation rate, and others. The stool-based biomarkers segment can be divided into faecal calprotectin, faecal lactoferrin, and others
· In stool-based biomarkers primarily calprotectin is used to detect irritable bowel diseases. Surge in FDA approvals for various assays and product advances are likely to boost the segment in the near future. BÜHLMANN fCAL turbo is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin. Gentian has, in cooperation with its partner BÜHLMANN, has been delivering the BÜHLMANN fCAL turbo to the market since 2016 and recorded an 81% sales growth in 2018, with sales reaching US$ 1.02 Mn.
Request COVID Analysis on Biomarker in Irritable Bowel Diseases Diagnostic Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78169
Hospitals segment to expand significantly
· Based on end user, the global biomarker in irritable bowel diseases diagnostic market can be divided into diagnostic laboratories, hospitals and research institutes.
· The diagnostic laboratories segment dominates the biomarker in irritable bowel diseases diagnostic market. Rise in awareness about preventive health and increase in targeted diseases boost the segment.
· However, the hospitals segment is expected to gain market share during the forecast period and expand at a significant CAGR during that time. Expansion of the segment can be attributed to a rise in the rate of hospitalization for inflammatory bowel diseases and wide range of services offered by hospitals at a single site. Rise in cases of irritable bowel diseases boosts the segment. Internationally, the incidence of IBD is around 0.5 to 24.5 cases per 100,000 person-years for ulcerative colitis and 0.1 to 16 cases per 100,000 person-years for Crohn’s disease.
Request Customization on Biomarker in Irritable Bowel Diseases Diagnostic Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=78169
North America to dominate global biomarker in irritable bowel diseases diagnostic market
· In terms of region, the global biomarker in irritable bowel diseases diagnostic market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
· In terms of revenue, North America dominated the biomarker in irritable bowel diseases diagnostic market in 2019, followed by Europe. High prevalence of diseases and well-established health care infrastructure that enables proper diagnosis of IBD are responsible for the high market share held by the region. According to a paper published in Gastroenterology & Hepatology journal, in 2017, there were 6·8 million cases of IBD globally, and the highest prevalence rate in 2017 occurred in high-income North America.
· However, the market in Asia Pacific is estimated to expand at a rapid pace during the forecast period primarily due to a rise in the prevalence of disorders and an increase in awareness about treatment in the region. Majority of countries in Asia Pacific are economically developing and numerous players are making significant investments in the region. These factors boost the market in Asia Pacific. Rise in technological advancements in countries in terms of health care and medical research is anticipated to fuel the market in the region. The incidence of Crohn’s disease has been increasing in countries in Asia in the last few years. A study conducted in 2013 reported the incidence of IBD at 0.54 to 3.44 per 100,000 in the region.
Pre Book Biomarker in Irritable Bowel Diseases Diagnostic Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=78169<ype=S
Key Manufacturers Operating in Market
The global biomarker in irritable bowel diseases diagnostic market was highly fragmented in 2019. Key manufacturers operating in the global market are:
· DiaSorin S.p.A.
· F. Hoffmann-La Roche Ltd
· Siemens Healthineers AG
· Abbott Laboratories
· Quidel Corporation
· BÜHLMANN Laboratories AG
· American Laboratory Products Company (ALPCO)
· Certest Biotec SL.
· Biosystems S.A.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact Us
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com
